IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
By Dr. Matthew Watson
NEW YORK, May 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced multiple presentations at the International Society for Cell & Gene Therapy 2024, to be held May 28th to June 1st in Vancouver, Canada.
Read the original post:
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
Related Post
- Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT - June 10th, 2024
- Y-mAbs Announces Preclinical GD2-SADA Data to be Presented at 2024 SNMMI Annual Meeting - June 10th, 2024
- Nusano Names D. Scott Holbrook as Chairman of its Board - June 10th, 2024
- TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - June 10th, 2024
- Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained... - June 10th, 2024
- Replimune to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - June 10th, 2024
- Epic Bio to Present IND-Enabling Data Package for EPI-321 at FSHD International Research Congress - June 10th, 2024
- PHAXIAM announces the availability of the preparatory documents for the Combined General Meeting of 28 June 2024 - June 10th, 2024
- Octane Medical acquires B. Braun’s global orthobiologics business - June 10th, 2024
- CORRECTION – Tevogen Bio Expresses Gratitude to Patients, First Responders, Elected Officials, and Members of the United States Congress for... - June 10th, 2024
- NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 10th, 2024
- Akero Therapeutics Presents Poster and Late-breaking Oral Presentation on EFX at the EASL Congress 2024 - June 10th, 2024
- Seniors in Metro Vancouver Invited to Participate in a Clinical Trial Assessing a New Immunomodulator Designed to Restore Immune Function in the... - June 10th, 2024
- Spectral Medical Inc. Announces Results of Annual Meeting of Shareholders - June 10th, 2024
- FDA Accepts Eisai’s Filing of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of... - June 10th, 2024
- 4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease... - June 10th, 2024
- European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer - June 10th, 2024
- Press release Biocartis NV: Biocartis Welcomes Gina Wallar, PhD as Chief Business Officer and Judith Vacchino, PhD as VP Global Marketing - June 10th, 2024
- Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix - June 10th, 2024
- Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization - June 10th, 2024
- Zealand Pharma announces positive CHMP opinion for dasiglucagon for treatment of severe hypoglycemia in diabetes from European Medicines Agency - June 2nd, 2024
- DBV Technologies Announces Plan to Implement ADS Ratio Change - June 2nd, 2024
- Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase... - June 2nd, 2024
- Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine - June 2nd, 2024
- Bavarian Nordic Submits Supplemental BLA Seeking U.S. FDA Approval of Freeze-Dried Formulation of Smallpox and Mpox Vaccine - June 2nd, 2024
- AB Science is providing a summary of the live webcast held on May 30, 2024, giving an update on the application for conditional marketing... - June 2nd, 2024
- Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib - June 2nd, 2024
- Mainz Biomed Reports Results of 2024 Annual General Meeting - June 2nd, 2024
- CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting - June 2nd, 2024
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous... - June 2nd, 2024
- Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual Meeting - June 2nd, 2024
- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical... - June 2nd, 2024
- Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting - June 2nd, 2024
- Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid... - June 2nd, 2024
- Y-mAbs Announces Publication of Preclinical GD2-SADA Data at 2024 ASCO Annual Meeting - June 2nd, 2024
- Ultimovacs Announces Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - June 2nd, 2024
- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical... - June 2nd, 2024
- SYS6002 (CRB-701) A Next-Generation Nectin-4 Targeting Antibody Drug Conjugate Continues to Demonstrate Encouraging Safety and Efficacy Observed in... - June 2nd, 2024
- Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in... - June 2nd, 2024
- Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive... - June 2nd, 2024
- Enterome Highlights High Complete Response Rate in Clinical Study of EO2463 for Indolent Non-Hodgkin Lymphoma at ASCO 2024 - May 25th, 2024
- Atrogi Announces Publication on Advancements in Combatting Obesity and Metabolic Complications - May 25th, 2024
- BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid... - May 25th, 2024
- Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress - May 25th, 2024
- Minutes of Annual General Meeting 2024 - May 25th, 2024
- Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit - May 25th, 2024
- Monopar Announces CFO Succession - May 25th, 2024
- Renovaro Inc. and Amsterdam UMC Cancer Center Poised to Advance Cancer Immunotherapy - May 25th, 2024
- Scilex Holding Company Sends Letter to U.S. House of Representatives on Illegal Market Manipulation of the Common Stock of Scilex Holding Company - May 25th, 2024
- BioSenic provides First Quarter 2024 Business Update - May 25th, 2024
- Purespring Therapeutics presents preclinical data at the 61st ERA Congress - May 25th, 2024
- Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress - May 25th, 2024
- Sobi Receives US FDA Fast Track Designation for Emapalumab-lzsg being investigated in Macrophage Activation Syndrome - May 25th, 2024
- Scilex Holding Company Announces it has been Added to the MSCI Global Microcap Index - May 25th, 2024
- Guerbet : Hugues Lecat appointed Chairman of the Board of Directors of Guerbet. - May 25th, 2024
- OpGen Receives Expected Nasdaq Notice Regarding Delayed Form 10-Q - May 25th, 2024
- Iovance Biotherapeutics to Present at Upcoming Conferences and Events - May 25th, 2024
- Rakovina Therapeutics Announces Debentureholder Election to Receive Shares in Partial Satisfaction of Debenture Interest Payment Obligations - May 25th, 2024
- Sobi to present new myelofibrosis data at the ASCO 2024 Annual Meeting - May 25th, 2024
- Avenue Therapeutics Announces Last Patient Last Visit in Phase 1b/2a Clinical Trial of AJ201 for the Treatment of Spinal and Bulbar Muscular Atrophy... - May 17th, 2024
- Thrive Bioscience Welcomes Todd Lewis as Chief Commercial Officer - May 17th, 2024
- Faron Founders and bexmarilimab Developers Selected as Finalists for the European Inventor Award 2024 - May 17th, 2024
- Assertio to Participate in AGP Healthcare Conference on May 21 - May 17th, 2024
- Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH - May 17th, 2024
- Tevogen Bio Appoints Former Police Chief & FBI National Academy Graduate, William Keane, as Vice President of Strategic Initiatives - May 17th, 2024
- Digital Utilities Ventures Completes Feed Earth Now Merger - Accelerates Growth of Regenerative Agriculture Movement - May 17th, 2024
- Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024 - May 17th, 2024
- Ventyx Biosciences to Participate in Three Upcoming Investor Conferences - May 17th, 2024
- Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference - May 17th, 2024
- New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with... - May 17th, 2024
- Harvard Bioscience, Inc. to Participate in the Benchmark Healthcare House Call Virtual Conference - May 17th, 2024
- BioSyent Releases Financial Results for Q1 2024 - May 17th, 2024
- BioSyent Declares Second Quarter 2024 Dividend - May 17th, 2024
- Lifecore Biomedical Completes Incremental Liquidity Initiatives - May 17th, 2024
- DBV Technologies Announces Results of its 2024 Combined General Meeting - May 17th, 2024
- Fortrea Appoints Machelle Sanders to Board of Directors - May 17th, 2024
- QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency - May 17th, 2024
- Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise - May 17th, 2024
- HUTCHMED Highlights Sovleplenib Phase III ESLIM-01 Study and Hematological Malignancy Programs Data to be Presented at the upcoming EHA2024 Congress - May 17th, 2024
- Telesis Bio Announces Reverse Stock Split - May 7th, 2024
Global News Feed
Comments Off on IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024 |
May 25th, 2024
This author published 5592 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research